Systemic inflammatory syndrome in children with <scp> <i>FARSA</i> </scp> deficiency
Fabienne Charbit‐Henrion, Roman Goguyer‐Deschaumes, Keren Borensztajn, Marc Mirande, Jérémy Berthelet, Fernando Rodrigues‐Lima, Anis Khiat, Marie‐Louise Frémond, Brigitte Bader‐Meunier, Marco M. Rodari, Luís Seabra, Gillian Rice, Marie Legendre, David Drummond, Laureline Berteloot, Charles‐Joris Roux, Nathalie Boddaert, Philippe Drabent, Thierry Jo Molina, Florence Lacaille, Manoëlle Kossorotoff, Nadine Cerf–Bensussan, Marianna Parlato, Alice Hadchouel
Abstract
Variants in aminoacyl-tRNA synthetases (ARSs) genes are associated to a broad spectrum of human inherited diseases. Patients with defective PheRS, encoded by FARSA and FARSB, display brain abnormalities, interstitial lung disease and facial dysmorphism. We investigated four children from two unrelated consanguineous families carrying two missense homozygous variants in FARSA with significantly reduced PheRS-mediated aminoacylation activity. In addition to the core ARS-phenotype, all patients showed an inflammatory profile associated with autoimmunity and interferon score, a clinical feature not ascribed to PheRS-deficient patients to date. JAK inhibition improved lung disease in one patient. Our findings expand the genetic and clinical spectrum of FARSA-related disease.